论文部分内容阅读
目的:研究对比卡培他滨与博来霉素分别联合顺铂治疗宫颈癌的疗效。方法:抽选2013年2月至2014年6月该院收治的宫颈癌患者126例,随机法分为观察组和对照组各63例,观察组给予卡培他滨联合顺铂化疗治疗,对照组给予博来霉素联合顺铂化疗治疗,均治疗6个疗程。比较两组患者总有效率及不良反应率。结果:观察组总有效率80.95%与对照组76.19%比较,差异无统计学意义(P>0.05)。观察组总不良反应率44.44%与对照组50.79%比较差异无统计学意义(P>0.05)。结论:卡培他滨和博来霉素联合顺铂对宫颈癌患者具有相同的疗效,临床可根据患者既往用药情况和用药习惯酌情选择。
Objective: To compare the efficacy of capecitabine combined with cisplatin in the treatment of cervical cancer. METHODS: 126 patients with cervical cancer admitted to the hospital from February 2013 to June 2014 were randomly selected and divided into observation group and control group each with 63 cases. The observation group was treated with capecitabine plus cisplatin chemotherapy. The group was treated with bleomycin and cisplatin for 6 cycles. The total effective rate and adverse reaction rate were compared between the two groups. Results: The total effective rate of observation group was 80.95% compared with 76.19% of control group, the difference was not statistically significant (P>0.05). The total adverse reaction rate in the observation group was 44.44% compared with 50.79% in the control group (P>0.05). CONCLUSIONS: Capecitabine and bleomycin combined with cisplatin have the same efficacy for patients with cervical cancer, and can be clinically selected according to the patient’s previous medication and medication habits.